Clinical trials: Dexamethasone
Healthy
A Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject
To investigate the efficacy of symptomatic therapy with topical steroids and antihistamines for application site reaction (ASR) after administration of SPM 962 in healthy subjects
- Trial name
- NCT01737931
- Testing
- Topical steroid (Dexamethasone), Topical antihistamine (Diphenhydramine)
- Where
- 2 sites in South Korea
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Multiple Myeloma
Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
This is a Phase 1/1b, open-label, dose-escalation study designed to evaluate the safety, pharmacokinetics, and to determine the recommended Phase 2 dose of ABBV-838 in subjects with relapsed and refractory multiple myeloma.
- Trial name
- NCT02462525
- Testing
- ABBV-838, Pomalidomide, Dexamethasone
- Where
- 19 sites in United States, France and 2 more
- Volunteers
- 74 people
- Sponsor
- AbbVie
Multiple Myeloma
Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
The primary objective of the study is to determine the safety and tolerability of I-131-CLR1404 as a single or multiple dose, with and without concurrent weekly dexamethasone, in patients with relapsed or refractory multiple…
- Trial name
- NCT02278315
- Testing
- I-131-CLR1404, dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Cellectar Biosciences, Inc.
Hematological Malignancy
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Primary Objective: Phase 1: To determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) of SAR650984 (Isatuximab).
- Trial name
- NCT01084252
- Testing
- Isatuximab SAR650984, Dexamethasone
- Where
- 59 sites in United States, Argentina and 15 more
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- Sanofi
COVID-19 Pneumonia
Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs
Assessment of the clinical effects of infusions of cryopreserved allogeneic multipotent mesenchymal stem cells of the placenta and umbilical cord for COVID-19 patients with acute respiratory distress syndrome.
- Trial name
- NCT04461925
- Testing
- Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells, Antibiotics, Hormones
- Where
- Ukraine
- Volunteers
- 30 people
- Sponsor
- Institute of Cell Therapy
Multiple Myeloma
Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
The primary purpose of the study is to evaluate the safety and efficacy and to generate PK and biomarker data for the combination of pomalidomide and low-dose dexamethasone in patients with refractory or relapsed and refractory…
- Trial name
- STRATUS (NCT01712789)
- Testing
- Pomalidomide, Dexamethasone
- Where
- 112 sites in Austria, Belgium and 18 more
- Volunteers
- 682 people
- Sponsor
- Celgene
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
This randomized phase III trial is studying APF530 and dexamethasone to see how well they work compared with palonosetron and dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for cancer.
- Trial name
- NCT00343460
- Testing
- APF530, dexamethasone, Palonosetron Hydrochloride
- Where
- 52 sites in United States
- Volunteers
- 1,428 people
- Sponsor
- Heron Therapeutics
COVID-19 Infection
Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
Treatment of patients hospitalised for management of moderate COVID-19 infection
- Trial name
- Neptuno (NCT04784559)
- Testing
- Plitidepsin, Dexamethasone, Remdesivir
- Where
- 28 sites in Brazil, Bulgaria and 6 more
- Volunteers
- 205 people
- Sponsor
- PharmaMar
Amyloidosis
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared with CyBorD alone in treatment of newly diagnosed amyloid light chain (AL)…
- Trial name
- NCT03201965
- Testing
- Cyclophosphamide, Bortezomib, Dexamethasone, 40 mg
- Where
- 140 sites in United States, Australia and 20 more
- Volunteers
- 416 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma, Multiple Myeloma in Relapse
Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients
This is a phase I/II study of perifosine in combination with bortezomib-with or without dexamethasone-for patients with relapsed or refractory multiple myeloma previously treated with bortezomib.
- Trial name
- NCT00401011
- Testing
- Perifosine, Bortezomib, Dexamethasone
- Volunteers
- 84 people
- Sponsor
- AEterna Zentaris
Multiple Myeloma
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
The purpose of this study is to determine 1) the safety and tolerability of multiple intravenous doses of anti-CXCR4 (BMS-936564) as monotherapy and as combination, and 2) the maximum tolerated dose (MTD) of BMS-936564 in…
- Trial name
- NCT01359657
- Testing
- Anti-CXCR4 (BMS-936564), Lenalidomide, Dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma, Lymphoma
Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
This is a multi-center, open-label, dose escalation and dose expansion, Phase 1 study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of CM313.
- Trial name
- NCT04818372
- Testing
- CM313-Dose escalation, CM313, Dexamethasone
- Where
- 3 sites in China
- Volunteers
- 87 people
- Sponsor
- Keymed Biosciences Co.Ltd
Multiple Myeloma
Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)
The purpose of this study is to compare the efficacy of pomalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of pomalidomide and low dose dexamethasone without pembrolizumab in terms of Progression-Free…
- Trial name
- NCT02576977
- Testing
- Pembrolizumab, Pomalidomide, Dexamethasone
- Volunteers
- 251 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetic Macular Edema
A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of diabetic macular edema.
- Trial name
- NCT00168389
- Testing
- Dexamethasone
- Where
- 10 sites in United States, Australia and 8 more
- Volunteers
- 494 people
- Sponsor
- Allergan
Multiple Myeloma
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
The purpose of this study is to compare the efficacy of daratumumab in combination with lenalidomide and dexamethasone to that of lenalidomide and dexamethasone in terms of progression-free survival (PFS) in participants with…
- Trial name
- NCT02252172
- Testing
- Daratumumab IV, Lenalidomide, Dexamethasone
- Where
- 206 sites in United States, Australia and 11 more
- Volunteers
- 737 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
This is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).
- Trial name
- KarMMa-3 (NCT03651128)
- Testing
- bb2121, Daratumumab, Pomalidomide
- Where
- 62 sites in United States, Belgium and 11 more
- Volunteers
- 386 people
- Sponsor
- Celgene
Cataract Extraction
PRO-232 in Patients Subjected to Cataract Surgery
The main objective of this study is to evaluate the efficacy and safety of the PRO-232 formulation manufactured by Laboratorios Sophia S.A. de C.V.
- Trial name
- PRO-232 (NCT07305987)
- Testing
- Moxifloxacin / Dexamethasone Ophthalmic Solution, Moxifloxacin Hydrochloride, Ophthalmic, Dexamethasone phosphate
- Where
- 2 sites in Mexico
- Volunteers
- 134 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Multiple Myeloma, Relapsed Cancer
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
The purpose of this study is to evaluate the safety and tolerability of ANV419 monotherapy followed by ANV419 in combination with lenalidomide plus low-dose dexamethasone or ANV419 in combination with daratumumab.
- Conditions
- Multiple Myeloma, Relapsed Cancer, Refractory Multiple Myeloma, Adult Disease
- Trial name
- NCT05641324
- Testing
- ANV419, Lenalidomide with low-dose dexamethasone, Daratumumab
- Where
- 11 sites in Denmark, France and 3 more
- Volunteers
- 4 people
- Sponsor
- Anaveon AG
Chemotherapy-Induced Nausea and Vomiting
A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting
NEPA-15-18 is a clinical study assessing safety of pro-netupitant and palonosetron, two antiemetic drugs, given with oral dexamethasone.
- Trial name
- NCT02517021
- Testing
- Pro-netupitant/Palonosetron, Netupitant/Palonosetron, Dexamethasone
- Where
- 74 sites in United States, Austria and 10 more
- Volunteers
- 405 people
- Sponsor
- Helsinn Healthcare SA
Primary Dysmenorrhea
Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary Dysmenorrhea
Dysmenorrhea is characterized as excruciating menstrual cramps of uterine origin and is one of the most prevalent gynecological illnesses.
- Trial name
- NCT06317064
- Testing
- Ibuprofen and Aprepitant
- Where
- Pakistan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lahore Medical Research Center, LLP